Premium
Dupilumab treatment ameliorates clinical and hematological symptoms, including blood eosinophilia, in patients with atopic dermatitis
Author(s) -
Yamauchi Teruo,
Sasaki Shun,
Lee Eun Seon,
Tamura Takayuki,
Seki Marina,
Miwa Tasuku,
Kobayashi Kae,
Saruta Yusuke,
Kitami Yuki,
Sueki Hirohiko,
Watanabe Hideaki
Publication year - 2021
Publication title -
international journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 93
eISSN - 1365-4632
pISSN - 0011-9059
DOI - 10.1111/ijd.15183
Subject(s) - medicine , atopic dermatitis , dupilumab , eosinophil , eosinophilia , eczema area and severity index , immunoglobulin e , immunology , atopy , scorad , gastroenterology , allergy , antibody , disease , dermatology life quality index , asthma
Background Atopic dermatitis (AD) is an allergic disease that affects individuals of various ages. Recently, the IL‐4/13 inhibitor dupilumab has gained regulatory approval for clinical use in AD patients. Dupilumab has been reported to reduce several markers of AD, including the serum levels of thymus and activation‐regulated chemokine (TARC/CCL17), blood lactate dehydrogenase (LDH), and serum total immunoglobulin E (IgE). Methods We retrospectively reviewed data from 40 AD patients who were treated with dupilumab. Eczema Area and Severity Index (EASI), Investigator’s Global Assessment (IGA), body surface area (BSA) scores, TARC, LDH, total IgE, and eosinophil count in peripheral blood were assessed for a total of 32 weeks. Results The EASI, IGA, and BSA scores improved significantly with treatment, indicating a reduction in AD severity. Serum TARC and LDH levels also significantly decreased with treatment. Serum IgE levels were unchanged at 2 weeks of treatment but decreased significantly between 4 and 32 weeks. The number of eosinophils in the peripheral blood decreased at 4, 16, and 32 weeks after treatment initiation. Conclusions Several studies have reported that serum TARC, LDH, and total IgE levels are reduced by dupilumab treatment. Our real‐world data are the first to demonstrate a reduction in blood eosinophilia in patients who receive clinical treatment with dupilumab.